Literature DB >> 30893522

Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study.

Jakob S Knudsen1, Reimar W Thomsen1, Anton Pottegård2, Filip K Knop3,4,5, Henrik T Sørensen1.   

Abstract

Highlights This population-based real-world prescription study characterized all new users of liraglutide in northern Denmark from 2009 to 2015. More than half (57%) the patients had liraglutide prescribed as part of drug combinations outside the originally approved indications. Comorbidities or diabetes complications were present in most patients, with the highest prevalence observed among the 73% of initiators who would have been ineligible for the Liraglutide Effect and Action in Diabetes (LEAD) 1-5 trials that led to liraglutide registration, underscoring the need for further post-marketing studies.
© 2019 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  cross-sectional studies; diabetes pharmacology; drug utilization; glucagon-like peptide-1 receptor; liraglutide

Mesh:

Substances:

Year:  2019        PMID: 30893522     DOI: 10.1111/1753-0407.12919

Source DB:  PubMed          Journal:  J Diabetes        ISSN: 1753-0407            Impact factor:   4.006


  2 in total

1.  Changes in type 2 diabetes incidence and mortality associated with introduction of HbA1c as diagnostic option: A Danish 24-year population-based study.

Authors:  Jakob S Knudsen; Signe S Knudsen; Adam Hulman; Daniel R Witte; Edward W Gregg; Torsten Lauritzen; Lars Pedersen; Henrik T Sørensen; Reimar W Thomsen
Journal:  Lancet Reg Health Eur       Date:  2022-01-01

2.  Hospitalization for hypoglycaemia in people with diabetes in Denmark, 1997-2017: Time trends in incidence and HbA1c and glucose-lowering drug use before and after hypoglycaemia.

Authors:  Mads Bisgaard Bengtsen; Jakob Schöllhammer Knudsen; Maria Bisgaard Bengtsen; Niels Møller; Reimar Wernich Thomsen
Journal:  Endocrinol Diabetes Metab       Date:  2021-01-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.